Shree Ganesh Biotech (India) Ltd - 539470 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In compliance with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please finds enclosed herewith Annual Secretarial Compliance Report of the Company for the financial year ended on 31st March, 2023 issued by secretarial auditor Mr. Haresh Kapuriya Practicing Company Secretaries. You are requested to take the same on your record. Thanking you. Shree Ganesh Biotech (India) Ltd - 539470 - Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015
With reference to the above, please find enclosed herewith Certificate under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 of the Company for the year ended 31.03.2023. Please find above and acknowledge the same. Thanking You. Shree Ganesh Biotech (India) Ltd - 539470 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyShree Ganesh Biotech (India) Ltd 2CIN NO.L70101WB1982PLC121196 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: NAMITA ACHARYA Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: KISHAN NAIDU Designation: CFO EmailId: [email protected] Date: 12/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Shree Ganesh Biotech (India) Ltd - 539470 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we herewith submit certificate from Satellite Corporate Services Private Limited, Registrar & Share Transfer Agent of the Company for the quarter ended on 31st March 2023. This is for your information and records. Thanking You, Shree Ganesh Biotech (India) Ltd - 539470 - Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period From April 1, 2022 To March 31, 2023.
The Company has appointed SATELLITE CORPORATE SERVICES PVT LTD having Registration No.INR000003639 as Registrar and Share Transfer Agent for handling share transfers and allied matters. Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure requirements) Regulation 2015, we do hereby confirm that for the financial year ended on March 31, 2023, all the activities in relation to both physical and electronic share transfer facilities for the Company, are maintained by Satellite Corporate Services Pvt Limited (CIN U65990MH1994PTC077057), having its Office at A-Wing Office No.106 and 107, Dattani Plaza, Andheri Kurla Road, East West Indl Estate, Sakinaka, Mumbai - 400 072. Shree Ganesh Biotech (India) Ltd - 539470 - Closure of Trading Window
Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and in terms of Company''s Code of Conduct for Prohibition of Insider Trading, the trading window for dealing in the securities of the Company will remain closed from 1st April, 2023 till 48 (Forty Eight) hours after the announcement/declaration of financial results for the quarter and Financial year ended on 31st March 2023. The date of proposed Board Meeting for considering the financial results for the quarter and Financial Year ended on 31st March 2023 shall be informed in the due course. Thanking you. Shree Ganesh Biotech (India) Ltd - 539470 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shreeji Capital Partners Shree Ganesh Biotech (India) Ltd - 539470 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shreeji Capital Partners Shree Ganesh Biotech (India) Ltd - 539470 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Corporation Shree Ganesh Biotech (India) Ltd - 539470 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Corporation